phosphonoacetic acid has been researched along with Neuroretinitis in 62 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a controlled trial of foscarnet in the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS), patients with non-immediately sight-threatening lesions were randomized to receive immediate treatment with foscarnet or foscarnet treatment delayed until the first signs of retinitis progression." | 9.07 | Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome. ( Polis, MA, 1992) |
| "We performed a multicenter, randomized, unblinded clinical trial (the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial) designed to compare ganciclovir with foscarnet in the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS)." | 9.07 | Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. ( , 1992) |
| "Circulating human immunodeficiency virus (HIV) p24 antigen levels were measured in 22 AIDS patients who had detectable serum antigen at baseline after induction and maintenance therapy of foscarnet for cytomegalovirus retinitis in phase I/II multicenter trials." | 9.07 | Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. ( Causey, DM; Davis, RB; Grieco, MH; Hooton, TM; Jacobson, MA; McKinley, GF; Parenti, DM; Reddy, MM; van der Horst, CM, 1992) |
| "To evaluate foscarnet sodium in treating cytomegalovirus retinitis in patients with AIDS." | 9.07 | A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. ( Baird, BF; Davey, RT; Davis, M; De Smet, MD; Falloon, J; Kovacs, JA; Palestine, AG; Polis, MA; Zunich, KM; Zurlo, JJ, 1991) |
| "Ganciclovir and Foscarnet were compared in an open randomised trial as treatment and secondary prophylaxis of cytomegalovirus (CMV) retinitis in patients with AIDS." | 9.07 | Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison. ( Gazzard, BG; Harman, C; Mathalone, B; Mitchell, S; Moyle, G, 1992) |
| "The use of ganciclovir in the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) is limited by marrow toxicity and by the development of resistance to this agent in CMV strains capable of causing progressive disease." | 8.78 | Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet. ( Jacobson, MA, 1992) |
| "Induction regimens of foscarnet and ganciclovir are highly effective in arresting cytomegalovirus (CMV) retinitis in patients with AIDS." | 8.78 | Foscarnet and ganciclovir in the treatment of cytomegalovirus retinitis. ( Polis, MA, 1992) |
| "The pyrophosphate analogue, foscarnet, selectively inhibits the DNA polymerase of human herpes viruses, including cytomegalovirus, and the reverse transcriptase of HIV." | 8.78 | Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. ( Chrisp, P; Clissold, SP, 1991) |
| "Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring greater than 6 mumols of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy." | 7.68 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. ( Drew, WL; Feinberg, J; Jacobson, MA; Miner, RD; O'Donnell, JJ; Parenti, D; Whitmore, PV, 1991) |
| "Ganciclovir and foscarnet are both effective for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome, but the benefits of either agent given alone are limited." | 7.68 | Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus. ( Butler, KM; De Smet, MD; Husson, RN; Jarosinski, P; Lovato, G; Manjunath, K; Montrella, K; Mueller, B; Nussenblatt, RB; Pizzo, PA, 1992) |
| "Foscarnet is an investigational antiviral agent that has been used effectively in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients." | 7.68 | Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. ( Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991) |
| " Following allogeneic bone marrow transplantation, he developed cytomegalovirus retinitis, which was treated successfully with trisodium phosphonoformate (foscarnet)." | 7.67 | Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation. ( Arthur, C; Ganly, PS; Goldman, JM; Schulenburg, WE, 1988) |
| "Ten patients with acquired immunodeficiency syndrome with newly diagnosed cytomegalovirus (CMV) retinitis were treated with an induction regimen of intravenous foscarnet, 60 mg/kg of body weight, administered as a 2-h infusion and repeated every 8 h for 14 days." | 7.67 | Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. ( Jacobson, MA; Mills, J; O'Donnell, JJ, 1989) |
| "Foscarnet has a low solubility and a high degree of ionization at physiologic pH, requiring it to be administered in higher doses and larger volumes." | 6.38 | Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. ( Jacobson, MA; O'Donnell, JJ, 1991) |
| "Eight patients with acquired immunodeficiency syndrome and serious CMV retinitis received 2-h intravenous infusions of foscarnet at a dosage of 60 mg/kg of body weight every 8 h for 14 days." | 5.28 | Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. ( Aweeka, F; Gambertoglio, J; Jacobson, MA; Mills, J, 1989) |
| "Foscarnet was discontinued because of adverse events in 3 (3%) of 97 patients, with treatment being stopped in 2 patients because of renal insufficiency and in 1 patient because of an acute neurologic disorder." | 5.28 | Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens. ( Brancon, C; Caumes, E; Cochereau-Massin, I; Dahan, R; Dohin, E; Gentilini, M; Katlama, C; Robinet, M; Rogeaux, O, 1992) |
| "To evaluate foscarnet sodium in treating cytomegalovirus retinitis in patients with AIDS." | 5.07 | A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. ( Baird, BF; Davey, RT; Davis, M; De Smet, MD; Falloon, J; Kovacs, JA; Palestine, AG; Polis, MA; Zunich, KM; Zurlo, JJ, 1991) |
| "Circulating human immunodeficiency virus (HIV) p24 antigen levels were measured in 22 AIDS patients who had detectable serum antigen at baseline after induction and maintenance therapy of foscarnet for cytomegalovirus retinitis in phase I/II multicenter trials." | 5.07 | Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. ( Causey, DM; Davis, RB; Grieco, MH; Hooton, TM; Jacobson, MA; McKinley, GF; Parenti, DM; Reddy, MM; van der Horst, CM, 1992) |
| "Ganciclovir and Foscarnet were compared in an open randomised trial as treatment and secondary prophylaxis of cytomegalovirus (CMV) retinitis in patients with AIDS." | 5.07 | Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison. ( Gazzard, BG; Harman, C; Mathalone, B; Mitchell, S; Moyle, G, 1992) |
| "We performed a multicenter, randomized, unblinded clinical trial (the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial) designed to compare ganciclovir with foscarnet in the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS)." | 5.07 | Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. ( , 1992) |
| "In a controlled trial of foscarnet in the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS), patients with non-immediately sight-threatening lesions were randomized to receive immediate treatment with foscarnet or foscarnet treatment delayed until the first signs of retinitis progression." | 5.07 | Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome. ( Polis, MA, 1992) |
| "The use of ganciclovir in the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) is limited by marrow toxicity and by the development of resistance to this agent in CMV strains capable of causing progressive disease." | 4.78 | Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet. ( Jacobson, MA, 1992) |
| " The antiviral agents ganciclovir and foscarnet are effective against CMV retinitis and gastrointestinal diseases, although dose-limiting adverse effects and the need for long-term maintenance therapy may hinder their use in many patients." | 4.78 | Treatment and prophylaxis of cytomegalovirus disease. ( Jacobson, PA; Levinson, ML, 1992) |
| "The pyrophosphate analogue, foscarnet, selectively inhibits the DNA polymerase of human herpes viruses, including cytomegalovirus, and the reverse transcriptase of HIV." | 4.78 | Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. ( Chrisp, P; Clissold, SP, 1991) |
| "Induction regimens of foscarnet and ganciclovir are highly effective in arresting cytomegalovirus (CMV) retinitis in patients with AIDS." | 4.78 | Foscarnet and ganciclovir in the treatment of cytomegalovirus retinitis. ( Polis, MA, 1992) |
| "Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring greater than 6 mumols of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy." | 3.68 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. ( Drew, WL; Feinberg, J; Jacobson, MA; Miner, RD; O'Donnell, JJ; Parenti, D; Whitmore, PV, 1991) |
| "Foscarnet and ganciclovir appear to be of similar effectiveness in halting active infection when given as induction therapy and in forestalling progression of disease when given as maintenance therapy in persons with AIDS who have cytomegalovirus (CMV) retinitis." | 3.68 | Therapeutic algorithm for treatment of cytomegalovirus retinitis in persons with AIDS. A roundtable summary. ( Balfour, HH; Drew, WL; Hardy, WD; Heinemann, MH; Polsky, B, 1992) |
| "Ganciclovir and foscarnet are both effective for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome, but the benefits of either agent given alone are limited." | 3.68 | Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus. ( Butler, KM; De Smet, MD; Husson, RN; Jarosinski, P; Lovato, G; Manjunath, K; Montrella, K; Mueller, B; Nussenblatt, RB; Pizzo, PA, 1992) |
| "Foscarnet is an investigational antiviral agent that has been used effectively in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients." | 3.68 | Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. ( Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991) |
| "Ten patients with acquired immunodeficiency syndrome with newly diagnosed cytomegalovirus (CMV) retinitis were treated with an induction regimen of intravenous foscarnet, 60 mg/kg of body weight, administered as a 2-h infusion and repeated every 8 h for 14 days." | 3.67 | Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. ( Jacobson, MA; Mills, J; O'Donnell, JJ, 1989) |
| " Following allogeneic bone marrow transplantation, he developed cytomegalovirus retinitis, which was treated successfully with trisodium phosphonoformate (foscarnet)." | 3.67 | Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation. ( Arthur, C; Ganly, PS; Goldman, JM; Schulenburg, WE, 1988) |
| "Foscarnet has a low solubility and a high degree of ionization at physiologic pH, requiring it to be administered in higher doses and larger volumes." | 2.38 | Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. ( Jacobson, MA; O'Donnell, JJ, 1991) |
| " Myelosuppression may be further exacerbated in AIDS patients by such other agents as zidovudine or trimethoprim/sulfamethoxazole, often necessitating dosage reductions or discontinuation of these agents in patients receiving ganciclovir." | 2.38 | Foscarnet sodium. ( Baltz, JK; Minor, JR, 1991) |
| "CMV disease is a major problem in AIDS, though with a different profile from that seen in other immunosuppressed patients." | 2.38 | Cytomegalovirus infection in the acquired immune deficiency syndrome. ( Pinching, AJ, 1989) |
| " An important direction for future clinical research is the development of more effective and less toxic therapy, as well as orally bioavailable drugs for maintenance therapy." | 2.37 | Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. ( Jacobson, MA; Mills, J, 1988) |
| "Cytomegalovirus retinitis is probably the result of hematogenous spread of the virus to the retina after systemic reactivation of a latent cytomegalovirus infection." | 2.37 | The diagnosis of cytomegalovirus retinitis. ( Bloom, JN; Palestine, AG, 1988) |
| "Among 347 AIDS patients seen at St Mary's Hospital, London between 1983 and 1989, cytomegalovirus (CMV) disease was observed in 75 (22%)." | 1.28 | Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival. ( Anderson, S; Beck, EJ; Coker, R; Coleman, D; Harris, JR; Main, J; Migdal, C; Peters, BS; Pinching, AJ, 1991) |
| "Fifty AIDS patients were investigated for human cytomegalovirus (HCMV) viraemia when potentially HCMV-related clinical symptoms or syndromes were observed." | 1.28 | Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia. ( Gaballo, A; Gerna, G; Milanesi, G; Parea, M; Percivalle, E; Zavattoni, M; Zipeto, D, 1991) |
| "Foscarnet was discontinued because of adverse events in 3 (3%) of 97 patients, with treatment being stopped in 2 patients because of renal insufficiency and in 1 patient because of an acute neurologic disorder." | 1.28 | Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens. ( Brancon, C; Caumes, E; Cochereau-Massin, I; Dahan, R; Dohin, E; Gentilini, M; Katlama, C; Robinet, M; Rogeaux, O, 1992) |
| "Eight patients with acquired immunodeficiency syndrome and serious CMV retinitis received 2-h intravenous infusions of foscarnet at a dosage of 60 mg/kg of body weight every 8 h for 14 days." | 1.28 | Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. ( Aweeka, F; Gambertoglio, J; Jacobson, MA; Mills, J, 1989) |
| " Maintenance therapy with DHPG would appear to be necessary to prevent relapse, but the logistics of this are difficult, and the effective dosage of DHPG is as yet uncertain." | 1.27 | Treatment of CMV retinitis in an AIDS patient. ( Acheson, JF; Bradbeer, C; Shah, SM; Spalton, DJ; Thin, RN, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (22.58) | 18.7374 |
| 1990's | 48 (77.42) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Healy, B | 1 |
| Hirsch, MS | 1 |
| Masur, H | 1 |
| Heinemann, MH | 2 |
| Polis, MA | 3 |
| Jacobson, MA | 11 |
| Jabs, DA | 1 |
| Butler, KM | 1 |
| De Smet, MD | 2 |
| Husson, RN | 1 |
| Mueller, B | 1 |
| Manjunath, K | 1 |
| Montrella, K | 1 |
| Lovato, G | 1 |
| Jarosinski, P | 1 |
| Nussenblatt, RB | 1 |
| Pizzo, PA | 1 |
| Salit, IE | 1 |
| Evans, JK | 1 |
| Scoular, A | 1 |
| Miller, RF | 1 |
| Wilson, RJ | 1 |
| Skolnik, PR | 1 |
| Deray, G | 1 |
| Katlama, C | 3 |
| Jacobs, C | 1 |
| Bachman, DM | 1 |
| Dohin, E | 1 |
| Caumes, E | 1 |
| Cochereau-Massin, I | 1 |
| Brancon, C | 1 |
| Robinet, M | 2 |
| Rogeaux, O | 1 |
| Dahan, R | 1 |
| Gentilini, M | 1 |
| Balfour, HH | 1 |
| Drew, WL | 2 |
| Hardy, WD | 1 |
| Polsky, B | 1 |
| Evans, LM | 1 |
| Grossman, ME | 1 |
| Cotte, L | 1 |
| Langlois, M | 1 |
| Trepo, C | 1 |
| Reddy, MM | 1 |
| Grieco, MH | 1 |
| McKinley, GF | 1 |
| Causey, DM | 1 |
| van der Horst, CM | 1 |
| Parenti, DM | 1 |
| Hooton, TM | 1 |
| Davis, RB | 1 |
| Levinson, ML | 1 |
| Jacobson, PA | 1 |
| Moyle, G | 1 |
| Harman, C | 1 |
| Mitchell, S | 1 |
| Mathalone, B | 1 |
| Gazzard, BG | 2 |
| Morris, DJ | 1 |
| Wood, CA | 1 |
| Feinberg, J | 1 |
| O'Donnell, JJ | 4 |
| Whitmore, PV | 1 |
| Miner, RD | 1 |
| Parenti, D | 1 |
| MacGregor, RR | 1 |
| Graziani, AL | 1 |
| Weiss, R | 1 |
| Grunwald, JE | 1 |
| Gambertoglio, JG | 1 |
| Palestine, AG | 2 |
| Baird, BF | 1 |
| Falloon, J | 1 |
| Kovacs, JA | 1 |
| Davey, RT | 1 |
| Zurlo, JJ | 1 |
| Zunich, KM | 1 |
| Davis, M | 1 |
| Marwick, C | 1 |
| Nightingale, SL | 1 |
| Peters, BS | 1 |
| Beck, EJ | 1 |
| Anderson, S | 1 |
| Coleman, D | 1 |
| Coker, R | 1 |
| Main, J | 1 |
| Migdal, C | 2 |
| Harris, JR | 2 |
| Pinching, AJ | 2 |
| Harb, GE | 1 |
| Bacchetti, P | 1 |
| Gerna, G | 1 |
| Zipeto, D | 1 |
| Parea, M | 1 |
| Percivalle, E | 1 |
| Zavattoni, M | 1 |
| Gaballo, A | 1 |
| Milanesi, G | 1 |
| Nelson, MR | 1 |
| Barter, G | 1 |
| Hawkins, D | 1 |
| Coker, RJ | 1 |
| Tomlinson, D | 1 |
| Horner, P | 1 |
| Chrisp, P | 1 |
| Clissold, SP | 1 |
| Paul, AA | 1 |
| Leeper, HF | 1 |
| Friberg, TR | 1 |
| Henderly, DE | 1 |
| Jampol, LM | 1 |
| Minor, JR | 1 |
| Baltz, JK | 1 |
| Fanning, MM | 2 |
| Read, SE | 2 |
| Benson, M | 1 |
| Vas, S | 1 |
| Rachlis, A | 2 |
| Kozousek, V | 1 |
| Mortimer, C | 1 |
| Harvey, P | 1 |
| Schwartz, C | 1 |
| Chew, E | 2 |
| Farese, RV | 1 |
| Schambelan, M | 1 |
| Hollander, H | 1 |
| Stringari, S | 1 |
| Lehoang, P | 1 |
| Girard, B | 1 |
| Marcel, P | 1 |
| Zazoun, L | 1 |
| Matheron, S | 1 |
| Rozenbaum, W | 1 |
| Morer, I | 1 |
| Lernestedt, JO | 1 |
| Mills, J | 4 |
| Aweeka, F | 2 |
| Gambertoglio, J | 2 |
| Wood, G | 1 |
| Whitby, M | 1 |
| Hogan, P | 1 |
| Frazer, I | 1 |
| Acheson, JF | 1 |
| Shah, SM | 1 |
| Spalton, DJ | 1 |
| Bradbeer, C | 1 |
| Thin, RN | 1 |
| Walmsley, SL | 1 |
| Vellend, H | 1 |
| Salit, I | 1 |
| Crowe, S | 1 |
| Levy, J | 1 |
| McManus, N | 1 |
| Bloom, JN | 1 |
| Ganly, PS | 1 |
| Arthur, C | 1 |
| Goldman, JM | 1 |
| Schulenburg, WE | 2 |
| Heley, A | 1 |
| Singer, DR | 1 |
| Fallon, TJ | 1 |
| Williams, G | 1 |
| Cohen, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Foscarnet-Ganciclovir CMV Retinitis Trial[NCT00000136] | Phase 3 | 234 participants (Actual) | Interventional | 1990-03-31 | Completed | ||
| Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component[NCT00000665] | 240 participants | Interventional | Completed | ||||
| A Phase II Randomized Controlled Trial of Immediate Versus Delayed Foscarnet Therapy in AIDS Patients With Non-Immediately Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due to Myelosuppression[NCT00000697] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn | |||
| A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure[NCT00000691] | Phase 2 | 156 participants | Interventional | Completed | |||
| Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome[NCT00000726] | Phase 1 | 53 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000136)
Timeframe: All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial.
| Intervention | participants (Number) |
|---|---|
| Foscarnet | 107 |
| Ganciclovir | 127 |
14 reviews available for phosphonoacetic acid and Neuroretinitis
| Article | Year |
|---|---|
Characteristics of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet.
Topics: Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Combination; Eye Infections, Viral; Fosc | 1992 |
Cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Diagnosis, Differe | 1992 |
Foscarnet and ganciclovir in the treatment of cytomegalovirus retinitis.
Topics: Cytomegalovirus Infections; Drug Therapy, Combination; Foscarnet; Ganciclovir; Humans; Phosphonoacet | 1992 |
Foscarnet-induced penile ulcer.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
Treatment and prophylaxis of cytomegalovirus disease.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Anemia; Animals; Antiviral Agents; Cytomegalovirus; Cytomegalovi | 1991 |
Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet.
Topics: Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Combination; Eye Infections, Viral; Fosc | 1991 |
Diagnosis and treatment of cytomegalovirus retinitis.
Topics: Antiviral Agents; Cytomegalovirus Infections; Diagnosis, Differential; Eye Infections, Viral; Foscar | 1991 |
Foscarnet sodium.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Cotton-wool spots and cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Cytomegalovirus Infections; Diabetic Retinopathy; Dia | 1989 |
Cytomegalovirus infection in the acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Addison Disease; Antiviral Agents; Colitis; Cytomegal | 1989 |
Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1988 |
The diagnosis of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Diagnos | 1988 |
8 trials available for phosphonoacetic acid and Neuroretinitis
| Article | Year |
|---|---|
The treatment of cytomegalovirus in AIDS--more than meets the eye.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Comb | 1992 |
Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Dose-Response Relationship, D | 1992 |
Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
AIDS file.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1991 |
A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1991 |
40 other studies available for phosphonoacetic acid and Neuroretinitis
| Article | Year |
|---|---|
From the National Institutes of Health.
Topics: Acquired Immunodeficiency Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Arthr | 1992 |
Foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Didanosine and foscarnet marketed for use by patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Didanosine; Foscar | 1992 |
Clinical implications of herpesvirus infections in patients with AIDS. Introduction.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Treatment of cytomegalovirus retinitis--1992.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus.
Topics: Antiviral Agents; Child, Preschool; Cytomegalovirus Infections; Drug Therapy, Combination; Female; F | 1992 |
Why was treatment of cytomegalovirus retinitis randomized?
Topics: Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Viral; Foscarnet; Ganciclovir; Humans; | 1992 |
Cytomegalovirus and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Comb | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Admini | 1992 |
Therapeutic algorithm for treatment of cytomegalovirus retinitis in persons with AIDS. A roundtable summary.
Topics: Acquired Immunodeficiency Syndrome; Adult; Algorithms; Cytomegalovirus Infections; Foscarnet; Gancic | 1992 |
Herpes simplex virus infection during foscarnet therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Foscarnet for CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infect | 1991 |
Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adult; Antiviral Agents; Cytomegalovirus In | 1991 |
National Eye Institute issues clinical alert about CMV retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Foscarnet approved for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; | 1991 |
From the Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Colitis; Cytomegalovirus Infections; Female; F | 1991 |
Survival of patients with AIDS and cytomegalovirus disease treated with ganciclovir or foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Female; Fos | 1991 |
Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia.
Topics: Acquired Immunodeficiency Syndrome; Antigens, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovi | 1991 |
Simultaneous treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1991 |
Treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Topics: Adult; Cytomegalovirus Infections; Drug Combinations; Foscarnet; Ganciclovir; HIV Seropositivity; Hu | 1991 |
Seeing the way forward for treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1991 |
CMV retinitis and the use of FK 506.
Topics: Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; Immunosuppression Therap | 1991 |
Foscarnet therapy of cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; | 1990 |
Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Diabetes In | 1990 |
Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Creatine; Cytomegalovirus Infections; Drug Therapy, Combi | 1989 |
Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Calcium; Cytomegalovirus Infections; Fo | 1989 |
Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1989 |
Foscarnet infusion at home.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Admini | 1989 |
Treatment of CMV retinitis in an AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1987 |
Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet).
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1988 |
Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; HIV; HI | 1988 |
Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation.
Topics: Adult; Antiviral Agents; Bone Marrow Transplantation; Busulfan; Cataract; Cytomegalovirus Infections | 1988 |
Foscarnet infusion at home.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Foscarnet; HIV Antigens; Home | 1988 |
Foscarnet for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; | 1985 |